One class of drugs has already found success in treating the painful, disorienting and common attacks. Excitement is building about a slew of additional drug targets.
Population and animal studies suggested it could treat cancer, but the clinical trials were a bust. Here’s what happened and what potential may remain.
Polygenic risk scores — a patient’s chance, based on tiny DNA variants, of developing cardiovascular disease, breast cancer and more — are coming to clinics. But there are kinks to iron out and accuracy remains an issue.
Fluctuating levels of estrogen during a period known as perimenopause can wreak havoc on the mental health of women in midlife. Diagnosis and treatment have been elusive despite symptoms as serious as suicidal thoughts.
Close X
Science journalism needs you! Make a tax-deductible gift by Dec. 31 to support our fact-checked stories.
